DE602004032465D1 - Referenzstandard zur charakterisierung von rosuvastatin - Google Patents

Referenzstandard zur charakterisierung von rosuvastatin

Info

Publication number
DE602004032465D1
DE602004032465D1 DE602004032465T DE602004032465T DE602004032465D1 DE 602004032465 D1 DE602004032465 D1 DE 602004032465D1 DE 602004032465 T DE602004032465 T DE 602004032465T DE 602004032465 T DE602004032465 T DE 602004032465T DE 602004032465 D1 DE602004032465 D1 DE 602004032465D1
Authority
DE
Germany
Prior art keywords
rosuvastatin
characterization
reference standard
standard
analysis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004032465T
Other languages
English (en)
Inventor
Nina Finkelstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34676616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602004032465(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of DE602004032465D1 publication Critical patent/DE602004032465D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
DE602004032465T 2003-12-02 2004-12-02 Referenzstandard zur charakterisierung von rosuvastatin Active DE602004032465D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52644903P 2003-12-02 2003-12-02
PCT/US2004/040329 WO2005056534A1 (en) 2003-12-02 2004-12-02 Reference standard for characterization of rosuvastatin

Publications (1)

Publication Number Publication Date
DE602004032465D1 true DE602004032465D1 (de) 2011-06-09

Family

ID=34676616

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004032465T Active DE602004032465D1 (de) 2003-12-02 2004-12-02 Referenzstandard zur charakterisierung von rosuvastatin

Country Status (13)

Country Link
US (6) US7244844B2 (de)
EP (1) EP1689723B1 (de)
JP (1) JP4733047B2 (de)
KR (1) KR100887264B1 (de)
CN (1) CN1894221B (de)
AT (1) ATE507209T1 (de)
CA (1) CA2546894C (de)
DE (1) DE602004032465D1 (de)
ES (1) ES2364143T3 (de)
IL (1) IL175511A (de)
PT (1) PT1689723E (de)
TW (1) TWI351958B (de)
WO (1) WO2005056534A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
DE602004032465D1 (de) * 2003-12-02 2011-06-09 Teva Pharma Referenzstandard zur charakterisierung von rosuvastatin
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
CA2591439C (en) * 2005-02-22 2013-03-26 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
AU2006329006B2 (en) * 2005-12-20 2013-02-28 Lek Pharmaceuticals D.D. Pharmaceutical composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid
JP5330225B2 (ja) * 2007-03-13 2013-10-30 テバ ファーマシューティカル インダストリーズ リミティド トリオール型ロスバスタチン
EP2189456A1 (de) * 2008-11-14 2010-05-26 LEK Pharmaceuticals d.d. Neue Omeprazol-Verbindungen
CN102325755B (zh) 2008-12-30 2015-07-01 艾科尔公司 取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物
CN103454352B (zh) * 2013-07-30 2015-07-15 广东先强药业有限公司 一种hplc法测定瑞舒伐他汀钙的含量及其有关物质的方法
CN103776939A (zh) * 2014-02-11 2014-05-07 润泽制药(苏州)有限公司 瑞舒伐他汀钙制剂有关物质的制备检测方法
CN108398501A (zh) * 2018-03-02 2018-08-14 海南通用三洋药业有限公司 一种检测瑞舒伐他汀钙有关物质的方法
CN109020902B (zh) * 2018-07-23 2020-06-02 唯智医药科技（北京）有限公司 一种瑞舒伐他汀钙杂质及其制备方法与用途
CN114280181A (zh) * 2021-12-23 2022-04-05 浙江海翔川南药业有限公司 一种瑞舒伐他汀中间体及其有关物质的检测方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37314A (en) * 1863-01-06 Improved composition for lemonade
US633198A (en) * 1899-02-08 1899-09-19 Wilhelm Magnus Hoekerstedt Automatic-lighting torch.
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
ES2110499T3 (es) * 1991-06-19 1998-02-16 Shionogi & Co Intermediario opticamente activo y su produccion.
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9626746D0 (en) 1996-12-23 1997-02-12 Knoll Ag Process
GB9812413D0 (en) * 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
SI20070A (sl) 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
TR200302281T2 (tr) * 2001-08-16 2004-09-21 Teva Pharmaceutical Industries Ltd. Statinlerin kalsiyum tuzu formlarını hazırlamak için işlemler
SE0103509D0 (sv) 2001-10-19 2001-10-19 Astrazeneca Ab Rosuvastatin in pre demented states
KR100511533B1 (ko) 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
AU2003228010A1 (en) * 2002-05-21 2003-12-02 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
HUP0500851A3 (en) 2002-12-10 2008-02-28 Ranbaxy Lab Ltd Process for the preparation of rosuvastatin
WO2005021511A1 (en) 2003-08-27 2005-03-10 Hetero Drugs Limited A novel process for amorphous rosuvastatin calcium
WO2005040134A1 (en) * 2003-10-22 2005-05-06 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
EP1601658A1 (de) * 2003-11-24 2005-12-07 Teva Pharmaceutical Industries Limited Kristalline ammoniumsalze von rosuvastatin
DE602004032465D1 (de) * 2003-12-02 2011-06-09 Teva Pharma Referenzstandard zur charakterisierung von rosuvastatin
WO2006035277A2 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
CA2594692A1 (en) 2005-01-31 2006-08-03 Ciba Specialty Chemicals Holding Inc. Crystalline forms of rosuvastatin calcium salt
EP1863773A1 (de) 2005-03-22 2007-12-12 Unichem Laboratories Limited Verfahren zur herstellung von rosuvastatin
WO2006106526A1 (en) 2005-04-04 2006-10-12 Unichem Laboratories Limited Process for preparation of calcium salt of rosuvastatin
WO2006136407A1 (en) 2005-06-24 2006-12-28 Lek Pharmaceuticals D.D. Process for preparing amorphous rosuvastatin calcium free of impurities
EP1915349B2 (de) 2005-06-24 2018-09-12 LEK Pharmaceuticals d.d. Verfahren zur herstellung von reinem amorphen rosuvastatin-calcium
GB0514078D0 (en) 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process

Also Published As

Publication number Publication date
US20090188305A1 (en) 2009-07-30
KR100887264B1 (ko) 2009-03-06
CA2546894C (en) 2009-09-08
US20070249830A1 (en) 2007-10-25
CN1894221A (zh) 2007-01-10
JP2007512354A (ja) 2007-05-17
IL175511A0 (en) 2006-09-05
US20070255059A1 (en) 2007-11-01
CA2546894A1 (en) 2005-06-23
ES2364143T3 (es) 2011-08-25
US7741482B2 (en) 2010-06-22
US20070244321A1 (en) 2007-10-18
US20050187234A1 (en) 2005-08-25
EP1689723B1 (de) 2011-04-27
IL175511A (en) 2011-11-30
TW200522959A (en) 2005-07-16
JP4733047B2 (ja) 2011-07-27
US7244844B2 (en) 2007-07-17
KR20060098396A (ko) 2006-09-18
PT1689723E (pt) 2011-07-06
EP1689723A1 (de) 2006-08-16
US8487097B2 (en) 2013-07-16
ATE507209T1 (de) 2011-05-15
CN1894221B (zh) 2012-08-08
US7692010B2 (en) 2010-04-06
WO2005056534A1 (en) 2005-06-23
US20070249831A1 (en) 2007-10-25
TWI351958B (en) 2011-11-11
US7692008B2 (en) 2010-04-06
US7692009B2 (en) 2010-04-06

Similar Documents

Publication Publication Date Title
IL175511A0 (en) Reference standard for characterization of rosuvastatin
ATE269295T1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
DE60007095D1 (de) Calanolide zur hemmung von btk
ATE335722T1 (de) Benzoylsulfonamide und sulfonylbenzamidine zur verwendung als antitumor-mittel
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
ATE307618T1 (de) Vorrichtung zur abgabe von flüchtigen stoffen
DE602004020901D1 (de) System zur Einführung von mehreren Medizinprodukten
EP1700120A4 (de) Marker für neuromyelitis optica
MA28985B1 (fr) Analogues de loxapine et methodes d'utilisation
DE60318831D1 (de) System zur abgabe von anästhetika
DE602004025507D1 (de) Vanillin-polymere zwecks verwendung zur verdunklung der haut
EA200500064A1 (ru) Многофункциональные маркеры продуктов и способы их получения и применения
DE60300407D1 (de) Vorrichtung zur Impedanzmessung lebender Körper
IL173929A0 (en) Analogues of kahalalide f and pharmaceutical compositions containing the same
ECSP045466A (es) Inhibidores de la peptido-desformilasa
DE502004011765D1 (de) Implantat zur Spreizung der Nasenflügel
UY27192A1 (es) Inhibidores de peptido-deformilasa
SE0301650D0 (sv) Novel compounds
DE60234250D1 (de) Vorrichtung zur Zell- bzw. Gewebezüchtung
DE602004026412D1 (de) Vorrichtung zur verhinderung von lasteinsturz
AU2003223634A1 (en) Peptide deformylase inhibitors
DE60200296D1 (de) Gerät zur Detektion von Vorsatzlöchern
AU2003304490A1 (en) Peptide deformylase inhibitors
AU2002258437A1 (en) Peptide deformylase inhibitors
IS7441A (is) Peptíðdeformýlasatálmar